论文部分内容阅读
随着支撑大型制药公司药品收入的重磅炸弹药物的专利到期以及传统的研发实验室对产出效率贡献的减少,生物技术公司将越来越多地被定位于填补创新药和产品线之间的空白。
With the expiration of patents for blockbuster drugs that support the revenue of large pharmaceutical companies and the reduced contribution of traditional R & D labs to output efficiency, biotechnology companies will increasingly be positioned to fill innovative medicines and product lines Between the blank.